pemetrexed + cisplatin
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastrointestinal Neoplasms
Conditions
Gastrointestinal Neoplasms
Trial Timeline
Sep 1, 2003 → Sep 1, 2005
NCT ID
NCT00190801About pemetrexed + cisplatin
pemetrexed + cisplatin is a phase 2 stage product being developed by Eli Lilly for Gastrointestinal Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00190801. Target conditions include Gastrointestinal Neoplasms.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (15)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00040625 | Pre-clinical | Completed |
| NCT01000480 | Phase 2 | Completed |
| NCT00887549 | Phase 2 | Completed |
| NCT00895648 | Phase 2 | Terminated |
| NCT00475657 | Phase 2 | Terminated |
| NCT00447421 | Phase 1/2 | Terminated |
| NCT00415168 | Phase 2 | Completed |
| NCT00386815 | Phase 2 | Completed |
| NCT00374868 | Phase 1/2 | Completed |
| NCT00259285 | Phase 2 | Terminated |
| NCT00251550 | Phase 1/2 | Completed |
| NCT00191308 | Phase 2 | Completed |
| NCT00320515 | Phase 1/2 | Completed |
| NCT00190801 | Phase 2 | Completed |
| NCT00087698 | Phase 2 | Completed |
Competing Products
20 competing products in Gastrointestinal Neoplasms